share_log

Truist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $18

Truist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $18

Truist Securities维持对Allogene Therapeutics的买入,将目标股价
Benzinga ·  2023/07/12 11:31

Truist Securities analyst Asthika Goonewardene maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target from $20 to $18.

Truist Securities分析师Asthika Goonewardene维持Allogene Therapeutics(纳斯达克股票代码:ALLO)的买入,并将目标股价从20美元下调至18美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发